Integral Ad Science (IAS) closed the last trading session at $10.77, gaining 0.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...
For patients with type 2 diabetes mellitus, semaglutide is associated with a reduced risk for a first-time Alzheimer disease (AD) diagnosis compared with other antidiabetic medications.